Masonic Cancer Center

A comprehensive cancer center designated by the National Cancer Institute

Clinical Pharmacology

The Clinical Pharmacology shared resource at the Masonic Cancer Center provides pharmacology services and expertise for funded cancer-related projects of Masonic Cancer Center members. Investigators are encouraged to contact the Clinical Pharmacology shared resource early in the planning stages of the project to assess feasibility and determine study design.

Video On Services Provided By The Clinical Pharmacology Shared Resource

Publication Acknowledgment Request

The Clinical Pharmacology Shared Resource receives grant support from the National Cancer Institute, which should be acknowledged in any publications. The following statement is suggested: "We would like to acknowledge the assistance of the Clinical Pharmacology Shared Resource of the Masonic Cancer Center, a comprehensive cancer center designated by the National Cancer Institute, supported in part by P30 CA77598."

We would appreciate a reprint of your publications.
We appreciate your acknowledgment of Clinical Pharmacology services in your publications.


Mark Kirstein, Pharm.D. 
Associate Professor of Clinical Pharmacology 
717 Delaware St., S.E., Room 459

Laboratory Manager
Jim Fisher, B.S.
Experimental and Clinical Pharmacology

AHCMCC2 - Image -500x150 - Clinical Pharmacology
  • Review pharmacology background
  • Pharmacokinetic/pharmacogenetic/pharmacodynamic study design
  • Write pharmacology components of grants and research protocols
Drug and Metabolite Analyses
  • Develop and validate assay methods for sample analysis
  • Human subject biological sample analyses (e.g., blood, plasma, PBMC, tumor)
Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Analyses
  • Pharmacokinetic analyses
  • Pharmacogenetic analyses
  • Pharmacodynamic analyses
  • Results interpretation
  • Author pharmacology components of abstracts, reports, and manuscript(s)
Equipment and Analysis Examples

High-performance liquid chromatography (HPLC) equipment

AHCMCC2 - Image -340x190 - HPLC-equipment

Gemcitabine and metabolite concentration time plots

AHCMCC2 - Image -340x190 - Gemcitabine

AHCMCC2 - Image -340x190 - Gemcitabine Triphosphate

Busulfan pharmacogenetics

AHCMCC2 - Image -340x190 - Busulfan pharmacogenetics

Post-hoc IV busulfan clearance estimates in patients with GSTA1*A/*A, GSTA1*A/*B and GSTA1*B/*B genotypes. The solid lines represent the means for each genotype.

Consultation for study design and feasibility are provided free of charge to researchers planning cancer-related grant applications and research protocols or conducting cancer-related research (pilot and feasibility studies).

Analytical service costs are recovered through percent (%) effort of personnel, supplies and instrument time.

Pharmacokinetic, pharmacodynamic, and pharmacogenetic modeling are provided free of charge for small studies (e.g., Phase I/II).

  • ©2014 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on April 27, 2016